CARM Carisma Therapeutics Inc.

CIK 0001485003 50 ready 8-Ks latest December 5, 2025, 6:59 PM ET RSS · JSON

Activity: NORMAL 0 filings / 30d vs 0 baseline

Ready 8-Ks 50

Latest filing December 5, 2025, 6:59 PM ET

Top materiality 1.00

Event mix other_material ×20 · m_and_a ×9 · earnings ×8

Sentiment 9 pos · 17 neg · 24 neu

Latest earnings reported 2024-Q3

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for CARM

Highest-materiality recent filing

Carisma Therapeutics to be delisted from Nasdaq on Oct 13; expects to wind down operations

October 9, 2025, 7:59 PM ET other material materiality 1.00 negative item 3.01 ◈ Listing & Compliance Notices

Received Nasdaq delisting letter; common stock suspended from trading effective Oct 13, 2025; no appeal planned.
Approval received to list common stock on OTCID market tier under symbol CARM starting Oct 13, 2025.

Read filing →

December 5, 2025, 6:59 PM ET other material materiality 0.90 negative item 3.01 item 5.02

Carisma voluntarily delisting from Nasdaq, terminating SEC reporting; appoints new CEO for wind-down

Board approved voluntary delisting from Nasdaq; Form 25 expected Dec 10; delisting effective 10 days later.
October 15, 2025, 7:59 PM ET leadership materiality 0.90 negative item 5.02 item 9.01

Carisma Therapeutics terminates CEO (eff. Nov 15) and CSO; three directors resign

CEO Steven Kelly terminated without cause, effective Nov 15, 2025; gets $624K severance plus $299,948 prorated bonus and health payments.
October 9, 2025, 7:59 PM ET other material materiality 1.00 negative item 3.01 ◈ Listing & Compliance Notices

Carisma Therapeutics to be delisted from Nasdaq on Oct 13; expects to wind down operations

Received Nasdaq delisting letter; common stock suspended from trading effective Oct 13, 2025; no appeal planned.
September 18, 2025, 7:59 PM ET other material materiality 0.95 negative item 1.01 item 1.02 item 8.01

Carisma terminates merger with OrthoCellix, receives $4M from Moderna, expects wind-down

Moderna pays $4M one-time to eliminate all future milestones, royalties, and research costs under the 2022 collaboration; licenses become fully paid-up and perpetual.
August 29, 2025, 7:59 PM ET M&A materiality 0.70 neutral item 1.01 item 3.02 item 5.01 item 5.02 item 8.01 item 9.01

Carisma enters $5M subscription deal with Ocugen; Nasdaq deadline extended to Oct 21

Subscription agreement with Ocugen for $5M private placement as part of concurrent $25M financing.
July 15, 2025, 7:59 PM ET regulatory materiality 0.85 negative item 3.01

Carisma receives Nasdaq delisting notice for bid price non-compliance; schedules Aug 5 reverse split vote

Nasdaq notified Carisma on July 9, 2025 that failure to regain bid price compliance is an additional delisting basis.
June 23, 2025, 7:59 PM ET M&A materiality 0.90 negative item 1.01 item 7.01 item 9.01

Carisma to merge with OrthoCellix; pre-merger holders to own ~10% of combined company

Carisma (CARM) enters merger with Ocugen subsidiary OrthoCellix; Merger Sub to merge into OrthoCellix, which becomes wholly owned subsidiary.
June 12, 2025, 7:59 PM ET other material materiality 0.70 neutral item 8.01

Carisma Therapeutics secures Nasdaq listing extension with transfer to Capital Market, strict conditions to Oct 7, 2025

Nasdaq Panel granted exception; listing transferred to Nasdaq Capital Market effective June 12, 2025.
April 16, 2025, 7:59 PM ET other material materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices ×3

Carisma receives Nasdaq delisting notice for MVLS, MVPHS, bid price non-compliance

Nasdaq notified Carisma on April 10, 2025, of delisting for failing to maintain $50M MVLS by April 8, 2025 compliance deadline.
January 10, 2025, 6:59 PM ET regulatory materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices ×2

Carisma Therapeutics receives Nasdaq bid price deficiency notice; has until July 7, 2025 to regain compliance

Received Nasdaq notice on Jan 6, 2025 for non-compliance with minimum bid price of $1.00 per share.
December 26, 2024, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01

Carisma Therapeutics appoints interim VP of Finance, principal accounting officer

Natalie McAndrew appointed interim VP of Finance effective Jan 1, 2025.
December 9, 2024, 6:59 PM ET other material materiality 0.80 negative item 2.05 item 5.02 item 8.01 ◈ Restructurings & Charges

Carisma Therapeutics reduces workforce by 34%, terminates CFO, discontinues lead candidate CT-0525

Reduction of 23 employees (34% of workforce); expects ~$2.7M in one-time termination costs, substantially complete by Q1 2025.
November 7, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Carisma Q3 net loss $12.7M; cash $26.9M; CT-0525 initial data expected Q1 2025

Net loss of $12.7M in Q3 2024 vs $21.4M in Q3 2023; R&D expenses fell to $11.3M from $19.6M.
October 11, 2024, 7:59 PM ET regulatory materiality 0.65 negative item 3.01

Carisma Therapeutics receives Nasdaq deficiency notice for market value below $50M

Nasdaq notified Carisma on Oct 10, 2024 that MVLS fell below $50M minimum requirement.
August 8, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Carisma Therapeutics Q2 2024 net loss $11.2M; CT-0525 data expected by year-end

Net loss improved to $11.2M in Q2 2024 from $19.9M in Q2 2023; R&D expenses declined to $15.3M.
July 9, 2024, 7:59 PM ET other material materiality 0.60 positive item 8.01 item 9.01

Carisma reports 75% ctDNA reduction in HER2 3+ patients in Phase 1 CT-0508 trial

75% (6/8) evaluable HER2 3+ patients had ctDNA reduction (median 81%, range 33%-93%); no reduction in 5 HER2 2+ patients.
July 2, 2024, 7:59 PM ET other material materiality 0.75 negative item 2.05 ◈ Restructurings & Charges

Carisma terminates Novartis manufacturing deal for CT-0508; pays $4M fee, suspends Phase 1 enrollment

Terminated Manufacturing and Supply Agreement with Novartis for CT-0508; effective July 31, 2024.
June 27, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Carisma nominates first in vivo CAR-M candidate under Moderna collab; $2M milestone triggered

Development candidate targets Glypican-3 for solid tumors, including hepatocellular carcinoma (HCC).
May 9, 2024, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01 ◈ Earnings Releases

Carisma Therapeutics Q1 net loss $19.0M; cash $56.5M; lead candidate CT-0525 prioritized

Net loss $19.0M for Q1 2024 vs $24.6M in Q1 2023; R&D expenses $17.5M.
April 10, 2024, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

Carisma reports preliminary Phase 1 data for CT-0508; 40.7% target lesion reduction in monotherapy

In 14 monotherapy patients, 40.7% of target lesions reduced in size on ≥1 scan across all anatomic sites.
April 1, 2024, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01 ◈ Earnings Releases

Carisma Therapeutics reports $86.9M net loss; prioritizes CT-0525, cuts workforce 37%

Cash of $77.6M as of Dec 31, 2023, expected to fund operations into Q3 2025 after restructuring.
November 9, 2023, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Carisma Therapeutics reports Q3 2023 net loss of $21.4M; cash $94.1M funds into Q1 2025

Net loss of $21.4M for Q3 2023 vs. $18.3M for Q3 2022.
September 1, 2023, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

Carisma Therapeutics Reports Phase 1 CT-0508 Data Showing Safety and Biomarker Correlation

CT-0508 is a HER2-targeted CAR-M therapy for HER2 overexpressing cancers; 14 patients treated across group 1 (n=9) and group 2 (n=5).
August 10, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Carisma Q2 net loss $19.9M, cash $117.1M; dosed first patient in CT-0508+KEYTRUDA combo trial

Dosed first patient in Phase 1 trial of CT-0508 in combination with KEYTRUDA for HER2-overexpressing solid tumors.
June 9, 2023, 7:59 PM ET other material materiality 0.60 neutral item 5.02 item 5.03 item 5.07 item 9.01 ◈ Shareholder Votes ×5◈ Governance Changes

Carisma shareholders approve tripling authorized common stock to 350M shares and incentive plan amendment

Authorized common stock increased from 100M to 350M shares (vote: 29.4M for, 1.6M against).
May 12, 2023, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

Carisma Therapeutics Q1 net loss widens to $24.6M; cash post-merger $139M

Net loss of $24.6M in Q1 2023, vs $11.3M in Q1 2022, driven by higher R&D and G&A expenses.
April 4, 2023, 7:59 PM ET other material materiality 0.60 negative item 2.02 item 9.01 ◈ Earnings Releases

Carisma FY2022 net loss $61.2M, rev $9.8M; merger closed

Net loss of $61.2M for year ended Dec 31, 2022 (basic EPS $54.65 loss); compared to $40.8M net loss in 2021.
March 8, 2023, 6:59 PM ET M&A materiality 0.85 neutral item 1.01 item 2.01 item 3.02 item 3.03 item 4.01 item 5.01 item 5.02 item 5.03 item 5.05 item 7.01 item 8.01 item 9.01 ◈ executive_change ×13◈ Auditor Changes ×2◈ Governance Changes ×2◈ M&A Transactions

Carisma Therapeutics completes reverse merger with Sesen Bio; begins trading as CARM

Merger closed March 7, 2023; Sesen Bio renamed Carisma Therapeutics; ticker changes from SESN to CARM on Nasdaq.
March 6, 2023, 6:59 PM ET other material materiality 0.75 positive item 8.01

Sesen Bio to pay $0.36/share special dividend and issue CVR upon merger close on March 7

Special cash dividend of $75M (~$0.36/share) payable by March 10 to holders of record March 7, contingent on merger closing.
March 2, 2023, 6:59 PM ET M&A materiality 0.90 positive item 3.03 item 5.07 item 5.03 item 8.01 item 9.01 ◈ Shareholder Votes ×5◈ Governance Changes

Sesen Bio stockholders approve merger with Carisma; declares $75M special dividend

Over 88% of votes cast approved the merger with Carisma Therapeutics; merger expected to close March 7, 2023.
February 28, 2023, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

Sesen Bio reports Q4 net loss $7.6M; reiterates support for Carisma merger ahead of shareholder vote

Q4 net loss $7.6M ($0.04/shr) vs net income $8.9M in Q4 2021; FY net loss $19.9M ($0.10/shr).
February 27, 2023, 6:59 PM ET regulatory materiality 0.70 neutral item 8.01

Sesen Bio gets Nasdaq exception to complete Carisma merger by March 10; delisting risk if not compliant

Nasdaq Panel granted exception from $1.00 bid price rule to complete merger with Carisma by March 10, 2023.
February 14, 2023, 6:59 PM ET M&A materiality 0.85 positive item 1.01 item 8.01 item 9.01 ◈ Material Agreements

Sesen Bio raises special dividend to $75M, extends CVR through 2027; activist investors back merger

Special cash dividend increased to $75M ($0.36/share) from prior ~$70M; up from original $25M.
February 7, 2023, 6:59 PM ET other material materiality 0.65 neutral item 8.01 item 9.01

Sesen Bio merger partner Carisma appoints Moderna CSO Lin Guey to SAB; merger on track for Q1 2023

Carisma Therapeutics appointed Lin Guey, PhD (Chief Scientific Officer of Moderna's External Research Ventures) to its Scientific Advisory Board.
February 2, 2023, 6:59 PM ET M&A materiality 0.80 positive item 8.01 item 9.01

Sesen Bio discloses ~$0.34/shr special dividend, 25.2% stake in combined company in Carisma merger

Expected one-time cash dividend of ~$70M ($0.34/shr) upon merger close; plus CVR up to $0.14/shr from legacy asset sales and Roche milestone.
February 1, 2023, 6:59 PM ET litigation materiality 0.75 positive item 8.01

Class action securities litigation settlement receives final court approval

U.S. District Court for Southern District of New York granted final approval on January 31, 2023.
January 31, 2023, 6:59 PM ET leadership materiality 0.60 positive item 8.01 item 9.01

Carisma appoints prominent oncologist to SAB; merger on track for Q1 2023

Padmanee Sharma, MD, PhD, from MD Anderson, appointed to Carisma's Scientific Advisory Board.
January 30, 2023, 6:59 PM ET regulatory materiality 0.85 negative item 3.01 item 9.01 ◈ Listing & Compliance Notices

Sesen Bio receives Nasdaq delisting notice; warns of dissolution if merger fails

Nasdaq notified Sesen on Jan 25, 2023 of non-compliance with $1.00 bid price; delisting unless hearing requested.
December 29, 2022, 6:59 PM ET M&A materiality 0.70 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements

Sesen Bio Amends Merger with Carisma: Special Dividend Raised to ~$70M, CVR Expanded

Expected special cash dividend increased from up to $25M to ~$70M ($0.34/share); up from ~$0.12.
December 23, 2022, 6:59 PM ET other material materiality 0.60 neutral item 1.02 ◈ Material Agreements

Sesen Bio terminates license agreement with Qilu Pharma; pays $1.4M termination fee

Terminated exclusive license agreement with Qilu Pharmaceutical for Vicineum in Greater China.
November 7, 2022, 6:59 PM ET M&A materiality 0.80 neutral item 2.02 item 9.01 ◈ Earnings Releases

Sesen Bio reports Q3 net income $20.5M, announces merger with Carisma Therapeutics

Merger with Carisma: Sesen stockholders own ~41.7%, Carisma ~58.3% of combined company with ~$180M cash.